Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. (FOLD) Too Early
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November.
Amicus Therapeutics Inc. (FOLD)
Market is closed
News
- First
- << Previous
- 41 - 50
- Next >>
Were Hedge Funds Right About Souring On Amicus Therapeutics, Inc. (FOLD)?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition...
Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds...
Hedge Fund and Insider Trading News: Warren Buffett, Elliott Management, Mcdonald’s Corp (MCD), GTT Communications Inc (GTT), Butler National Co. (BUKS), and More
Warren Buffett’s Berkshire Hathaway Inc. is hopping on the fintech bandwagon.
Hedge Fund and Insider Trading News: Ken Griffin, Carl Icahn, Howard Hughes Corp (HHC), Amicus Therapeutics, Inc. (FOLD), Falcon Minerals Corp (FLMN), and More
Billionaire Ken Griffin hired two veteran money managers from Louis Bacon’s hedge fund as he seeks to build a rival macro business.
Hedge Fund and Insider Trading News: Bill Miller, John Paulson, Warren Buffett, Amicus Therapeutics, Inc. (FOLD), Workday Inc (WDAY), and More
Famed investor Bill Miller is still a believer in Facebook. "This too will pass," he said in an email to CNBC's Scott Wapner.
Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA
President Donald Trump in his inaugural speech to a joint session of Congress characterized the approval process of drugs at the U.S. Food and Drug Administration as burdensome and slow.
Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes
Amicus Therapeutics, Inc. (NASDAQ:FOLD) says that it will be closing its previously announced private offering of $250 million aggregate principal amount of 3.00% convertible senior notes due 2023.
Amicus Therapeutics, Inc. (FOLD): Breaking Down The Raise
Amicus Therapeutics, Inc. (NASDAQ:FOLD) just announced a convertible senior notes offering, and the company is trending down on he back of the news.
- First
- << Previous
- 41 - 50
- Next >>
Billionaire Hedge Funds
